FDA Issues Orphan Status Approval for PermaDerm®
07:24 EDT 12 Jun 2012 | Bio-Medicine
LITTLE FALLS, N.J., June 12, 2012 /- Regenicin, Inc. (OTC Bulletin Board: RGIN ) a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organ..
Original Article: FDA Issues Orphan Status Approval for PermaDerm®
More From BioPortfolio on "FDA Issues Orphan Status Approval for PermaDerm®"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
